• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

FDA Clears Orasis Pharmaceuticals’ Presbyopia Treatment


Qlosi indicated for adult patients.

40's man with glasses with presbyopia looking at the phone. Image Credit: Adobe Stock Images/Marcos Ferreiro

Image Credit: Adobe Stock Images/Marcos Ferreiro

Orasis Pharmaceuticals announced that the FDA has officially approved Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of Presbyopia in adult patients. According to the company, it is a prescription eye drop that can be used daily, or as needed, up to twice per day. The medication is expected to be available in the US during the first half of next year.

"The FDA approval of QLOSI marks a tremendous milestone for Orasis as we continue our mission to provide a flexible treatment option for the millions of people in the U.S. living with presbyopia, or blurry near vision," said Elad Kedar, CEO, Orasis Pharmaceuticals. "I am grateful to the Orasis team, our strategic partners, clinical investigators, and patients who participated in our clinical trials, all of whom made this achievement possible."

Reference: Orasis Pharmaceuticals Announces FDA Approval of QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the Treatment of Presbyopia. PR Newswire. October 18, 2023. Accessed October 18, 2023. https://www.prnewswire.com/news-releases/orasis-pharmaceuticals-announces-fda-approval-of-qlosi-pilocarpine-hydrochloride-ophthalmic-solution-0-4-for-the-treatment-of-presbyopia-301959581.html?tc=eml_cleartime

Related Videos
Related Content